The New York City-based drugmaker’s second quarter revenue increased 11 percent year over year to $13.2 billion.
Prevnar, a vaccine for pneumococcal diseases, saw a decline in sales posting $1.26 billion, compared to the $1.58 billion analysts predicted, according to Bloomberg.
Sales of Ibrance — Pfizer’s new breast cancer drug — more than tripled to hit $514 million, surpassing analysts’ estimate of $498 million.
Pfizer’s new arthritis pill Xeljanz posted 217 million in sales, beating its $199 million projection.
Pfizer reported total earnings of $2.02 billion, or 33 cents a share, a decrease from the $2.63 billion, or 42 cents per share, the company recorded for the second quarter of 2015.
More articles on the drug market:
Express Scripps adds new drugs to its exclusion list
Teva must divest 79 generics to acquire Allergan’s generic pharma for $40.5 billion
MIT researchers create programmable device to produce biologics on the spot
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
